DYAX: Dyax Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp.

DYAX 38.41

0.0%

Jan 25 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	9/5/2007 9:10:08 AM
	of 197

Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic Antibodies Wednesday September 5, 7:30 am ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX - News) announced today that they have entered into an agreement with Bayer Schering Pharma AG for the discovery of therapeutic antibodies. Under the terms of this agreement, Dyax will identify therapeutic antibodies for two targets provided by Bayer Schering Pharma. Furthermore, these research activities may be expanded to allow Dyax to work on additional targets and/or allow Bayer Schering Pharma to exercise an option for an antibody library license. Dyax will receive clinical milestone payments and royalties on net sales that may result from Bayer Schering Pharma's development and commercialization of any antibodies discovered through the collaboration. The agreement also provides Bayer Schering Pharma with sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology. Financial terms were not disclosed. "Dyax consistently generates new therapeutic antibody technology collaborations and has developed into one of the leaders in the industry for antibody drug discovery," commented Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax. "We are excited about the growing value of our Licensing and Funded Research Program, and look forward to building on its success in the future."...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next